These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 16551208

  • 1. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia.
    Black L, Naslund MJ, Gilbert TD, Davis EA, Ollendorf DA.
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S99-S110. PubMed ID: 16551208
    [Abstract] [Full Text] [Related]

  • 2. An evaluation of the economic costs and patient-related consequences of treatments for benign prostatic hyperplasia.
    DiSantostefano RL, Biddle AK, Lavelle JP.
    BJU Int; 2006 May; 97(5):1007-16. PubMed ID: 16542339
    [Abstract] [Full Text] [Related]

  • 3. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
    Kutikova L, Bowman L, Chang S, Long SR, Obasaju C, Crown WH.
    Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
    [Abstract] [Full Text] [Related]

  • 4. Comparison of health care costs and co-morbidities between men diagnosed with benign prostatic hyperplasia and cardiovascular disease (CVD) and men with CVD alone in a US commercial population.
    Shah M, Butler M, Bramley T, Curtice TG, Fine S.
    Curr Med Res Opin; 2007 Feb; 23(2):417-26. PubMed ID: 17288695
    [Abstract] [Full Text] [Related]

  • 5. Urologic diseases in America project: benign prostatic hyperplasia.
    Wei JT, Calhoun E, Jacobsen SJ.
    J Urol; 2005 Apr; 173(4):1256-61. PubMed ID: 15758764
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies.
    Yu X, Elliott SP, Wilt TJ, McBean AM.
    J Urol; 2008 Jul; 180(1):241-5; discussion 245. PubMed ID: 18499180
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Benign prostatic hyperplasia in Sweden 1987 to 1994: changing patterns of treatment, changing patterns of costs.
    Blomqvist P, Ekbom A, Carlsson P, Ahlstrand C, Johansson JE.
    Urology; 1997 Aug; 50(2):214-9; discussion 219-20. PubMed ID: 9255291
    [Abstract] [Full Text] [Related]

  • 12. Durability and cost-effectiveness of transurethral needle ablation of the prostate as an alternative to transurethral resection of the prostate when alpha-adrenergic antagonist therapy fails.
    Rosario DJ, Phillips JT, Chapple CR.
    J Urol; 2007 Mar; 177(3):1047-51; discussion 1051. PubMed ID: 17296409
    [Abstract] [Full Text] [Related]

  • 13. Economic costs of benign prostatic hyperplasia in the private sector.
    Saigal CS, Joyce G.
    J Urol; 2005 Apr; 173(4):1309-13. PubMed ID: 15758787
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical and economic outcomes in patients treated for enlarged prostate.
    Naslund MJ, Issa MM, Grogg AL, Eaddy MT, Black L.
    Am J Manag Care; 2006 Mar; 12(4 Suppl):S111-6. PubMed ID: 16551204
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
    Maddux FW, Shetty S, del Aguila MA, Nelson MA, Murray BM.
    Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.